Groupama Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Groupama Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-9,921	Closed	-$547K	–	457
2025 Q2	$547K	Sell	9,921 -2,897	-23%	-$171K	0.01%	318
2025 Q1	$916K	Sell	12,818 -90,606	-88%	-$6.1M	0.02%	265
2024 Q4	$6.77M	Buy	103,424 +7,340	+8%	+$492K	0.14%	95
2024 Q3	$5.42M	Buy	96,084 +483	+0.5%	+$40.4K	0.14%	103
2024 Q2	$7.87M	Buy	95,601 +1,290	+1%	+$107K	0.11%	111
2024 Q1	$9.37M	Sell	94,311 -6,442	-6%	-$577K	0.17%	105
2023 Q4	$9.72M	Buy	+100,753	New	+$8.91M	0.25%	76

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Groupama Asset Management's BMRN Position: Q3 2025 in Review

Groupama Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 9,921 shares — an estimated $547K sold.

Groupama Asset Management first reported a position in BMRN in Q4 2023 and held it in 7 quarters. The position peaked at $9.72M in Q4 2023. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

Groupama Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Groupama Asset Management sold 9,921 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $547K.
Groupama Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 7 quarters.
Groupama Asset Management's BioMarin Pharmaceuticals position peaked at $9.72M in Q4 2023.
576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Groupama Asset Management's 13F filing for Q3 2025, filed 1 Dec 2025.